key: cord-0758436-01t0hvmh authors: Ritter, Oliver; Kararigas, Georgios title: Sex-Biased Vulnerability of the Heart to COVID-19 date: 2020-09-18 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.09.017 sha: 7ecf7ee804176eb5813c65ef2e6326ebc5fb8360 doc_id: 758436 cord_uid: 01t0hvmh nan Currently, actual death rates associated with COVID-19 cannot be calculated with accuracy. Among others, this is due to availability of testing modalities and selection procedures for testing, as well as asymptomatic disease, all leading to undetected cases, thereby impacting the estimation of death rates. Nevertheless, on the basis of data released from several countries and a recent study employing a multinational COVID-19 registry, 1 despite similar infection rates or even in some cases more female than male infections, men appear to be disproportionately affected by COVID-19 and at higher risk of mortality than women. A significant proportion of COVID-19 patients have underlying cardiovascular disease (CVD). Importantly, it appears that elderly individuals with coronary heart disease or hypertension are more likely to be infected and to develop more severe symptoms. Consequently, CVD and hypertension are generally associated with increased crude fatality rates. Although sex-disaggregated data are currently scarce, it is not unreasonable to expect that the proportion of COVID-19 patients with CVD would be predominantly male. 2 This could be an explanation for the increased mortality observed in male COVID-19 patients and is a hypothesis that can be tested as data become available. However, independent of pre-existing cardiovascular conditions, increasing evidence supports a link between COVID-19 and increased morbidity and mortality from cardiovascular complications. Generally, respiratory infections are associated with a short-term increase in cardiovascular risk and the emerging data show that COVID-19 patients have acute coronary events. Myocardial injury was demonstrated by elevated cardiac biomarkers, i.e. high sensitivity Troponin I, indicating myocardial ischemia or non-ischemic myocardial events, including myocarditis. This is not surprising, given the severe respiratory infection and hypoxia due to J o u r n a l P r e -p r o o f among patients who died, substantial cardiac damage was observed. All these findings have been discussed in detail. 3 We put forward that male COVID-19 patients have an elevated risk of cardiovascular complications, thereby contributing to increased mortality. In light of this hypothesis, we propose here potential mechanisms implicated in COVID-19 pathogenesis that may provoke cardiovascular injury and dysfunction in a sex-biased manner, contributing to a greater risk in male patients (Figure) The coronavirus SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a host cell entry receptor. 8 ACE2 is an X-linked gene with male-biased expression in several tissues, including the heart. 9 However, it is currently unclear how circulating and tissue concentrations of ACE2 could influence SARS-CoV-2 susceptibility and disease virulence in the heart. In patients with heart failure, plasma concentrations of ACE2 were found to be higher in men than in women, with the study's authors suggesting that this might explain the higher incidence and fatality rate of COVID-19 in men. 10 However, soluble ACE2 converts angiotensin II, a potent vasoconstrictor also involved in cell proliferation, hypertrophy, generation of oxidative radicals and inflammation, into angiotensin 1-7, an angiotensin with antioxidant and anti-inflammatory effects, which further decreases angiotensin II levels. As a functional receptor on the cell surface also for SARS-CoV, ACE2 is down-regulated via endocytosis upon viral entry into cells. 8, 11 As a result, there is decreased availability of ACE2 for shedding, thereby affecting soluble ACE2 levels and angiotensin II production, ultimately promoting further pro-inflammatory effects, oxidative stress and vasoconstriction. 11 In this context, there appears to be an important distinction in the potential regulatory role between the membrane-bound and soluble forms of ACE2, with the latter conferring protection. Consequently, lower soluble ACE2 levels may be a contributing factor to increased vulnerability of male patients to COVID-19, accounting for imbalance of the renin-angiotensin-aldosterone system. Assessment of soluble and membranebound ACE2 levels in the presence of SARS-CoV-2 and the interplay with biological sex would contribute to clarifying this seemingly conflicting situation indicating the complexity of the renin-angiotensin-aldosterone system. J o u r n a l P r e -p r o o f cardiovascular (patho)physiology 7 and could be relevant to sex-dependent cardiovascular morbidity and mortality in COVID-19 patients, ultimately leading to male-biased susceptibility and severity. Certainly, this is an area for future investigation. Although strategies, such as social distancing, to slow the transmission of the virus are important, hospitals need to be prepared to care for cardiovascular complications in COVID-19 patients. This is particularly important given that several therapeutic agents evaluated for the treatment of COVID-19 have not been shown to be efficacious. In light of the present theory, there has to be extra consideration of sex-specific aspects in the management of these patients. Subsequently, treatment strategies for cardiovascular complications arising from COVID-19 are necessary, which, however, include the sex-biased epidemiologic observations made so far. Along this line, overall immunomodulation may be among the therapeutic options for targeting pathways discussed here. In particular, anti-inflammatory drugs/immunosuppressive agents, cytokine inhibitors, monoclonal antibodies, including anti-interleukin-1 and anti-interleukin-6, could protect against cardiac injury particularly in male patients. A glucocorticoid and interferon-backbone combination regimen could also confer cardiovascular benefit. Complement inhibitors, anticoagulants, antiplatelets and fibrinolytics may also be important components of a combination therapy in COVID-19 patients protecting against cardiovascular complications. Furthermore, considering the potentially sex-biased imbalance of the renin-angiotensinaldosterone system, soluble human recombinant ACE2 would be expected to be beneficial. Several trials are underway. However, there is a lack of sex-specific analysis in the emerging J o u r n a l P r e -p r o o f concepts and in the development of treatment strategies. Nevertheless, the interaction of biological sex with potential pharmacologic agents under investigation and clinical testing should not be neglected. 12 Early identification of risk factors for morbidity and mortality is necessary at times of a pandemic and overwhelmed healthcare systems to facilitate appropriate care and prompt access to treatment strategies for those at highest risk. Cardiovascular comorbidities and complications are common in patients with COVID-19. Male patients appear to be at higher risk of mortality and we have highlighted potential mechanisms that may provoke cardiovascular injury and dysfunction in a sex-dependent manner. However, it is currently unclear if biological sex imposes an independent risk or there is an effect of other (pre-existing) factors, e.g. smoking and limited intensive care support. We call upon public health agencies and health care systems to report and release sex-disaggregated data to facilitate further analyses. Sex Differences in COVID-19 Case Fatality Rate: Insights From a Multinational Registry Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy Potential Effects of Coronaviruses on the Cardiovascular System: A Review Sex-Specific Human Cardiomyocyte Gene Regulation in Left Ventricular Pressure Overload Sex-dependent regulation of fibrosis and inflammation in human left ventricular remodelling under pressure overload Molecular and Cellular Differences in Cardiac Repair of Male and Female Mice Mechanistic Pathways of Sex Differences in Cardiovascular Disease SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Landscape of X chromosome inactivation across human tissues Circulating plasma concentrations of angiotensinconverting enzyme 2 in men and women with heart failure and effects of reninangiotensin-aldosterone inhibitors A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury En route to precision medicine through the integration of biological sex into pharmacogenomics Potential mechanisms of sex-biased cardiovascular risk in COVID-19 patients. Biological sex leads to male-biased regulation of several pathomechanisms that may contribute to increased cardiovascular vulnerability of male patients to COVID-19, thereby leading to worse outcomes RAAS = renin-angiotensin-aldosterone system